These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19284062)

  • 1. Observational studies of drug-eluting stents--some are more equal than others.
    Austin D; Oldroyd KG; Pell JP
    EuroIntervention; 2009 Jan; 4(4):419, 421, 423. PubMed ID: 19284062
    [No Abstract]   [Full Text] [Related]  

  • 2. The relative safety and efficacy of bare-metal and drug-eluting stents in low and high-risk patient subsets. An epidemiological analysis of three sequential cohorts of consecutive all comers (n = 6129).
    Daemen J; van Twisk PH; Kukreja N; van Domburg RT; Boersma E; de Jaegere P; Serruys PW
    EuroIntervention; 2009 Jan; 4(4):464-74. PubMed ID: 19284068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the U.S. ARRIVE 1 registry: 2-year outcomes.
    Kornowski R
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):446-7. PubMed ID: 18819146
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The gender paradox.
    Presbitero P
    EuroIntervention; 2009 Jan; 4(4):415, 417. PubMed ID: 19284061
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A commentary on Diabetic and non-diabetic patients with left main and/ or three-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents by Banning AP et al.
    Marx N
    Diab Vasc Dis Res; 2011 Apr; 8(2):173. PubMed ID: 21562069
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute and long-term outcomes of ostial stentings among bare-metal stents, sirolimus-eluting stents, and paclitaxel-eluting stents.
    Hsieh IC; Hsieh MJ; Chang SH; Wang CY; Lee CH; Lin FC; Chen CC
    Coron Artery Dis; 2013 May; 24(3):224-30. PubMed ID: 23571311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: the Korean Multicenter Angioplasty Team (KOMATE) Registry.
    Kim JS; Lee BH; Ko YG; Choi D; Jang Y; Min PK; Yoon YW; Hong BK; Kwon HM; Ahn MS; Lee SH; Yoon JH; Lee BK; Kim BO; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Jung JH; Ryu SK;
    Catheter Cardiovasc Interv; 2008 Nov; 72(5):601-7. PubMed ID: 18942123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Girasis C; Piazza N; Garcia-Garcia HM; Kukreja N; Garg S; Eindhoven J; Cheng JM; Valgimigli M; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2010 Jun; 3(6):584-94. PubMed ID: 20630451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bifurcation stenting: a commitment to always kiss.
    Hillegass WB
    Catheter Cardiovasc Interv; 2010 Mar; 75(4):614-5. PubMed ID: 20333659
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of drug-eluting stents in women: a window of opportunity.
    Jacobs AK
    JACC Cardiovasc Interv; 2009 Jul; 2(7):611-3. PubMed ID: 19628182
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
    Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G
    JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Another small step for small vessels.
    Morrison DA
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):67-9. PubMed ID: 20578195
    [No Abstract]   [Full Text] [Related]  

  • 18. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction.
    Lee MS; Sillano D; Latib A; Chieffo A; Zoccai GB; Bhatia R; Sheiban I; Colombo A; Tobis J
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):15-21. PubMed ID: 19089930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crush stenting with paclitaxel-eluting or sirolimus-eluting stents for the treatment of coronary bifurcation lesions.
    Chen S; Zhang J; Ye F; Zhu Z; Lin S; Tian N; Liu Z; Fang W; Chen Y; Sun X; Kwan TW
    Angiology; 2008; 59(4):475-83. PubMed ID: 18388098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.